Epidermal growth factor receptor (EGFR) mutations are the most common mutations in NSCLC, there have been a series of studies showing that concomitant mutations are associated with inferior efficacy of EGFR TKI therapy (18, 19). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.